Major urinary protein-1 increases energy expenditure and improves glucose intolerance through enhancing mitochondrial function in skeletal muscle of diabetic mice

J Biol Chem. 2009 May 22;284(21):14050-7. doi: 10.1074/jbc.M109.001107. Epub 2009 Mar 31.

Abstract

Major urinary protein-1 (MUP-1) is a low molecular weight secreted protein produced predominantly from the liver. Structurally it belongs to the lipocalin family, which carries small hydrophobic ligands such as pheromones. However, the physiological functions of MUP-1 remain poorly understood. Here we provide evidence demonstrating that MUP-1 is an important player in regulating energy expenditure and metabolism in mice. Both microarray and real-time PCR analysis demonstrated that the MUP-1 mRNA abundance in the liver of db/db obese mice was reduced by approximately 30-fold compared with their lean littermates, whereas this change was partially reversed by treatment with the insulin-sensitizing drug rosiglitazone. In both dietary and genetic obese mice, the circulating concentrations of MUP-1 were markedly decreased compared with the lean controls. Chronic elevation of circulating MUP-1 in db/db mice, using an osmotic pump-based protein delivery system, increased energy expenditure and locomotor activity, raised core body temperature, and decreased glucose intolerance as well as insulin resistance. At the molecular level, MUP-1-mediated improvement in metabolic profiles was accompanied by increased expression of genes involved in mitochondrial biogenesis, elevated mitochondrial oxidative capacity, decreased triglyceride accumulation, and enhanced insulin-evoked Akt signaling in skeletal muscle but not in liver. Altogether, these findings raise the possibility that MUP-1 deficiency might contribute to the metabolic dysregulation in obese/diabetic mice, and suggest that the beneficial metabolic effects of MUP-1 are attributed in part to its ability in increasing mitochondrial function in skeletal muscle.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / enzymology
  • Diabetes Mellitus, Experimental / physiopathology*
  • Dietary Fats / administration & dosage
  • Dietary Fats / pharmacology
  • Energy Metabolism* / drug effects
  • Feeding Behavior / drug effects
  • Glucose Intolerance / complications
  • Glucose Intolerance / physiopathology*
  • Insulin / pharmacology
  • Insulin Resistance
  • Lipid Metabolism / drug effects
  • Liver / drug effects
  • Liver / metabolism
  • Liver / physiopathology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Obese
  • Mitochondria / drug effects
  • Mitochondria / metabolism*
  • Motor Activity / drug effects
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / enzymology
  • Muscle, Skeletal / physiopathology*
  • Proteins / metabolism*
  • Proto-Oncogene Proteins c-akt / metabolism
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / pharmacology
  • Rosiglitazone
  • Signal Transduction / drug effects
  • Thiazolidinediones / pharmacology
  • Up-Regulation / drug effects

Substances

  • Dietary Fats
  • Insulin
  • Proteins
  • Recombinant Proteins
  • Thiazolidinediones
  • major urinary proteins
  • Rosiglitazone
  • Proto-Oncogene Proteins c-akt